DR3

DR3バックグランド

Tumor necrosis factor receptor superfamily member 25 (TNFRSF25) is also known as Apo-3, Death receptor 3 (DDR3 or DR3), Apoptosis-inducing receptor AIR, Apoptosis-mediating receptor TRAMP, Lymphocyte-associated receptor of death, Apo-3, which is a member of the TNF-receptor superfamily. TNFRSF25 is a homodimer protein, which can Interact strongly via the death domains with TNFRSF1 and TRADD to activate at least two distinct signaling cascades, apoptosis and NF-kappa-B signaling. TNFRSF25 is receptor for TNFSF12 / APO3L / TWEAK.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
OntamalimabSHP-647; PF-00547659; PF-547659Phase 3 ClinicalPfizer IncIleitis; Colitis, Ulcerative; Crohn Disease
詳細
Vedolizumab biosimilar (Polpharma Biologics)PB-016Phase 3 ClinicalPolpharma Biologics SaPouchitis; Colitis, Ulcerative; Crohn Disease
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
VedolizumabMLN-0002; LPD-02; MLN-002; MLN-02; LDP-02ApprovedMillennium Pharmaceuticals Inc安吉优, EntyvioUnited StatesColitis, Ulcerative; Crohn DiseaseTakeda Pharmaceuticals USA Inc2014-05-20Celiac Disease; Carcinoma, Non-Small-Cell Lung; Melanoma; Crohn Disease; Gastritis; Urogenital Neoplasms; Colitis, Ulcerative; Cholangitis, Sclerosing; Pediatric ulcerative colitis; Solid tumours; Colitis; Pouchitis; Neoplasms; Pediatric Crohn's disease; Inflammatory Bowel Diseases; HIV Infections; Hematopoietic stem cell transplantation (HSCT)
詳細
  • 製品リスト
  • 市販薬剤に関する情報
  • 治験薬に関する情報